Unpad Gets Support from BRIN to Form the Teranostic Radiopharmaceutical Research Collaboration Center
Professor of the Faculty of Pharmacy, Universitas Padjadjaran (Unpad) Muchtaridi initiated the Research Collaboration Center (PKR) for Teranostic Radiopharmaceuticals supported by the National Research and Innovation Agency (BRIN). PKR is an effort to build a collaborative ecosystem for therapeutic radiopharmaceutical research.
PKR is based on Unpad's ability to encourage the development of Radiopharmaceutical research and the preparation of nuclear human resources, especially in the Faculty of Pharmacy and Faculty of Medicine. Currently, the Unpad Faculty of Pharmacy is a pioneer in preparing nuclear human resources through the Nuclear Pharmacy Specialist Program and the Unpad Faculty of Medicine which previously had the Nuclear Medicine Special Program.
These nuclear human resources will then contribute to services at the Nuclear Medicine Hospital, government agencies, and the pharmaceutical industry. In the PKR of Teranostic Radiopharmaceuticals, a number of human resources from various experts participated.
Such as pharmacists/pharmacist specialists in nuclear pharmacy, radiochemist, chemist, radiation biologist, medical physics, nuclear physics, biophysics, radiation protection, radiographer, veterinarian and nuclear medicine specialist.
These staff include professors who come from various higher education institutions, namely Unpad, UI, ITB, and STFI, as well as from RSHS, Dharmais Hospital, MRCCC Siloam Hospital Semanggi, and BRIN.
As the implementation of this PKR activity, a hybrid Radiofarmaka PKR Coordination Meeting was held from the Plenary Meeting Room of the Faculty of Pharmacy Unpad, Jatinangor. The event was attended by researchers from all participating institutions.
The PKR Coordination Meeting was opened by the Deputy Dean for Learning, Student Affairs, and Research at the Faculty of Pharmacy, Aliya Nurhasanah. He hopes that PKR can produce reputable international publications, increase the number of patents, the number of prototypes, and increase the number of doctoral graduates with the topic of therapeutic radiopharmaceuticals. As well as strengthening cooperation both nationally and internationally in research collaboration and downstreaming of RF products.
"With the capabilities of its human resources, facilities and resources, I believe that PKR will one day become the Center for Excellence in Teranostic Radiopharmaceutical Science and Technology in Indonesia, which has a broad impact on improving people's welfare, especially in the treatment of cancer and infection," said Aliya, quoted from the unpad.ac.id page. , Thursday, October 27, 2022.
Muchtaridi, who is the Head of the Collaborative Center for Teranostic Radiopharmaceutical Research, explained that the preparation of radiopharmaceutical raw materials begins with the synthesis of pharmaceuticals as compounds that will bind to certain receptors in the form of peptides, proteins, antibodies, isolates of natural ingredients and other compounds. These new pharmaceutical products developed by Unpad and STFI include isolates from natural ingredients and synthetic products from modified isolates and the synthesis of peptides and their conjugates.
Then, proceed with the optimization process of radiolabeling, in-vitro testing, preclinical testing, and dosimetry calculations developed by radiopharmaceutical researchers, radiochemists, and radiation biologists at the ORTN Facility, especially at the Research Center for Radioisotope Technology, Radiopharmaceuticals and Biodosimetry (PRTRRB).
In the advanced stage, imaging with gamma cameras, radiation protection and radiation safety is carried out by the Research Center for Nuclear Safety, Metrology and Quality Technology (PRTKMMN).
The University of Indonesia and the Bandung Institute of Technology play a role in modeling radiopharmaceutical pharmacokinetics in test animals by mathematical modeling and determining the value of time-integrated activity coefficient (TIAC) in test animals as well as radiopharmaceutical radiation transport modeling to determine the distribution of absorbed radiation dose in humans.
At the stage of scale-up of radiopharmaceutical products and registration documents, PRTRRB cooperates with pharmaceutical industry partners. As a new stage, radiopharmaceutical products that have met the requirements of the preclinical stage will proceed to the clinical trial stage involving several hospitals with nuclear medicine facilities, such as Hasan Sadikin Hospital in Bandung, Dharmais Cancer Hospital and MRCCC Siloam Hospital Semanggi Jakarta.